BIOA
$21.22
Post-MarketAs of Mar 17, 8:00 PM UTC
BioAge Labs, Inc.
Recent News
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion
BioAge Labs (NASDAQ:BIOA) outlined its strategy and near-term clinical plans at Oppenheimer’s 36th Annual Life Science Conference, emphasizing its focus on using human aging biology to develop therapies for metabolic disease. Co-founder and CEO Kristen Fortney was joined by team members BJ Sullivan
Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
The promising anti-inflammation target could be the next big thing in cardiovascular and other diseases.
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Wednesday Amid Continued Tariff Threats, Investors Await President Trump's Speech at Davos
The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.1%, and the actively t
BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio
BioAge shares catapulted Monday on promising results for the company's cardiovascular diseases treatment, which could eventually rival Eli Lilly.
2 Reasons I Wouldn't Touch BioAge Labs Stock With a 10-Foot Pole
Don't be too quick to jump on this biotech bandwagon.